Latest Breaking News On - Eurofins biopharma services - Page 1 : comparemela.com

Eurofins Scientific: Eurofins Delivers Strong Margin Improvement and Cash Generation in H2 2023 and Annual Results in Line With Its 2023 Objectives Remains Confident to Achieve Its 2027 Objectives

Eurofins Scientific: Eurofins Delivers Strong Margin Improvement and Cash Generation in H2 2023 and Annual Results in Line With Its 2023 Objectives Remains Confident to Achieve Its 2027 Objectives
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

United statesNew zealandNorth carolinaNew south walesAndhra pradeshSouth africaCastellon de la planaRepublic ofDominican republicMounds viewSaudi arabiaGilles martinAsia pacificEurofins panlabsEurofins celltxHolland pike

Eurofins Core Business Organic Growth Accelerates Above Its Objectives in H1 2023

Eurofins Core Business Organic Growth Accelerates Above Its Objectives in H1 2023
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United kingdomDominican republicPhnom penhUnited statesCastellon de la planaNew zealandAndhra pradeshSaudi arabiaEurofins technologieEurofins viracorEurofins celltxGilles martinForensic servicesEuronext paris stock exchangeGrowth in eurofins biopharma servicesMaterial sciences

Rare Event Analysis in Flow Cytometry: Design Control and Validation Aligned with CLSI H62, Upcoming Webinar Hosted by Xtalks

Toronto, ON (PRWEB) March 15, 2023 Rare event analysis by flow cytometry is relatively common in research settings, in clinical laboratories and during

Vera kovacevicEurofins biopharma servicesHoneycomb worldwide incScientific affairsDesign controlVirginia litwinRare event analysisFlow cytometryValidation alignedLife sciencePress release

CRO Emmes signs new five-year service agreement with Eurofins Central Laboratory

CRO Emmes signs new five-year service agreement with Eurofins Central Laboratory
prweb.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prweb.com Daily Mail and Mail on Sunday newspapers.

United statesUnited kingdomTracy hendershottLaboratory testingEurofins biopharma servicesEurofins central laboratoryClinical research organizationEurofins groupEuronext paris stock exchangeCentral laboratoryEurofins centralInfectious diseasesOrphan reachPresident commercial operationsBiopharma servicesEuronext paris stock

BetterLife Engages Eurofins Discovery for its Next Generation Psychedelics 2-bromo-LSD FDA IND-enabling Pharmacology Studies

NPAU), an emerging biotech company focused on the development and commercialization of cutting-edge treatments in mental disorders and viral infections, announces it has entered into an agreement with Eurofins Discovery for TD-0148A’s U.S. FDA Investigational New Drug (“IND”)-enabling pharmacology studies. TD-0148A is a second-generation Lysergic Acid Diethylamide (“LSD”) derivative molecule that BetterLife believes will mimic the projected therapeutic potential of LSD without causing the undesirable psychoactive dissociative side effects, such as hallucinations. Following our recent acquisition of the assets of Transcend Biodynamics, we are excited to be initiating the IND-enabling studies for TD-0148A. We look forward to working with Eurofins Discovery to bring this treatment to patients as quickly as possible as we prepare for our IND and trials, said BetterLife s Chief Executive Officer, Dr. Ahmad Doroudian.

British columbiaAhmad doroudianEurofins cerepWendy parenteauBetterlife pharmaEurofins biopharma servicesMarketing communicationsNuclear hormone receptorsBetterlife pharma incQlife pharmaEurofins discoveryNew drugLysergic acid diethylamideTranscend biodynamicsChief executive officerIon channels